We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in our Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Journal Scan / Research · September 07, 2022

Optimizing 68Ga-PSMA–PET/CT for Lymph Node Staging in Patients With Prostate Cancer by Integrating SUVmax Values and Hematological Inflammatory Markers

The Prostate


Additional Info

The Prostate
Optimization of prostate cancer patient lymph node staging via the integration of neutrophil-lymphocyte ratios, platelet-lymphocyte ratios, and 68 Ga-PSMA-PET-derived SUVmax values
Prostate 2022 Jul 21;[EPub Ahead of Print], Y Wang, Y Tang, X Gao, Y Gan, S Hu, MF Chen, Y Cai

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading